Search

Your search keyword '"van Gorp T"' showing total 394 results
Start Over Author "van Gorp T"
394 results on '"van Gorp T"'

1. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

Author

Van Gorp, T., Cibula, D., Lv, W., Backes, F., Ortaç, F., Hasegawa, K., Lindemann, K., Savarese, A., Laenen, A., Kim, Y.M., Bodnar, L., Barretina-Ginesta, M.-P., Gilbert, L., Pothuri, B., Chen, X., Flores, M.B., Levy, T., Colombo, N., Papadimitriou, C., Buchanan, T., Hanker, L.C., Eminowicz, G., Rob, L., Black, D., Lichfield, J., Lin, G., Orlowski, R., Keefe, S., Lortholary, A., and Slomovitz, B.

Published
2024
Full Text
View/download PDF

6. Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors

Author

Coosemans, A, primary, Ceusters, J, additional, Landolfo, C, additional, Baert, T, additional, Froyman, W, additional, Heremans, R, additional, Thirion, G, additional, Claes, S, additional, Oosterlynck, J, additional, Wouters, R, additional, Vankerckhoven, A, additional, Moro, F, additional, Mascilini, F, additional, Neumann, A, additional, Van Rompuy, AS, additional, Schols, D, additional, Billen, J, additional, Van Gorp, T, additional, Vergote, I, additional, Bourne, T, additional, Van Holsbeke, C, additional, Chiappa, V, additional, Scambia, G, additional, Testa, A, additional, Fischerova, D, additional, Timmerman, D, additional, and Van Calster, B, additional

Published
2024
Full Text
View/download PDF

8. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Author

Loverix L., Vergote I., Busschaert P., Vanderstichele A., Venken T., Boeckx B., Harter P., Brems H., Van Nieuwenhuysen E., Pignata S., Baert T., Gonzalez-Martin A., Han S., Marth C., Neven P., Colombo N., Berteloot P., Mäenpää J., Olbrecht S., Laga T., Sablon E., Ray-Coquard I., Pujade-Lauraine E., Lambrechts D., Van Gorp T., Loverix, L, Vergote, I, Busschaert, P, Vanderstichele, A, Venken, T, Boeckx, B, Harter, P, Brems, H, Van Nieuwenhuysen, E, Pignata, S, Baert, T, Gonzalez-Martin, A, Han, S, Marth, C, Neven, P, Colombo, N, Berteloot, P, Mäenpää, J, Olbrecht, S, Laga, T, Sablon, E, Ray-Coquard, I, Pujade-Lauraine, E, Lambrechts, D, and Van Gorp, T

Subjects
Targeted therapy, Cancer Research, PARP inhibitor, Oncology, Ovarian cancer, HRD testing, Leuven HRD test
Abstract

Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLUS [Myriad test]). Patients and methods: The academic Leuven HRD test consists of capture-based targeted sequencing of genome-wide single-nucleotide polymorphisms and coding exons of eight HR genes including BRCA1, BRCA2, and TP53. We compared the predictive value of the Leuven HRD versus Myriad HRD test for PFS and OS in the randomised PAOLA-1 trial. Results: 468 patients had left-over DNA after Myriad testing for Leuven HRD testing. Positive/negative/overall percent agreement for the Leuven versus Myriad HRD status was 95%/86%/91%, respectively. Tumours were HRD+ in 55% and 52%, respectively. In Leuven HRD+ patients, 5 years PFS (5yPFS) was 48.6% versus 20.3% (HR 0.431; 95% confidence intervals (CI) 0.312–0.595) for olaparib versus placebo, respectively (Myriad test 0.409; 95% CI 0.292–0.572). In Leuven HRD+/BRCAwt patients 5yPFS was 41.3% versus 12.6% (HR 0.497; 95% CI 0.316–0.783), and 43.6% versus 13.3% (HR 0.435; 95% CI 0.261–0.727) for the Myriad test. 5yOS was prolonged in the HRD+ subgroup with both tests 67.2% versus 54.4% (HR 0.663; 95% CI 0.442–0.995) for the Leuven test, and 68.0% versus 51.8% (HR 0.596 95% CI 0.393–0.904) for the Myriad test. HRD status was undetermined in 10.7% and 9.4% of the samples, respectively. Conclusions: A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.

Published
2023
Full Text
View/download PDF

10. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Author

Loverix, L, Vergote, I, Busschaert, P, Vanderstichele, A, Venken, T, Boeckx, B, Harter, P, Brems, H, Van Nieuwenhuysen, E, Pignata, S, Baert, T, Gonzalez-Martin, A, Han, S, Marth, C, Neven, P, Colombo, N, Berteloot, P, Mäenpää, J, Olbrecht, S, Laga, T, Sablon, E, Ray-Coquard, I, Pujade-Lauraine, E, Lambrechts, D, Van Gorp, T, Loverix L., Vergote I., Busschaert P., Vanderstichele A., Venken T., Boeckx B., Harter P., Brems H., Van Nieuwenhuysen E., Pignata S., Baert T., Gonzalez-Martin A., Han S., Marth C., Neven P., Colombo N., Berteloot P., Mäenpää J., Olbrecht S., Laga T., Sablon E., Ray-Coquard I., Pujade-Lauraine E., Lambrechts D., Van Gorp T., Loverix, L, Vergote, I, Busschaert, P, Vanderstichele, A, Venken, T, Boeckx, B, Harter, P, Brems, H, Van Nieuwenhuysen, E, Pignata, S, Baert, T, Gonzalez-Martin, A, Han, S, Marth, C, Neven, P, Colombo, N, Berteloot, P, Mäenpää, J, Olbrecht, S, Laga, T, Sablon, E, Ray-Coquard, I, Pujade-Lauraine, E, Lambrechts, D, Van Gorp, T, Loverix L., Vergote I., Busschaert P., Vanderstichele A., Venken T., Boeckx B., Harter P., Brems H., Van Nieuwenhuysen E., Pignata S., Baert T., Gonzalez-Martin A., Han S., Marth C., Neven P., Colombo N., Berteloot P., Mäenpää J., Olbrecht S., Laga T., Sablon E., Ray-Coquard I., Pujade-Lauraine E., Lambrechts D., and Van Gorp T.

Abstract

Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLUS [Myriad test]). Patients and methods: The academic Leuven HRD test consists of capture-based targeted sequencing of genome-wide single-nucleotide polymorphisms and coding exons of eight HR genes including BRCA1, BRCA2, and TP53. We compared the predictive value of the Leuven HRD versus Myriad HRD test for PFS and OS in the randomised PAOLA-1 trial. Results: 468 patients had left-over DNA after Myriad testing for Leuven HRD testing. Positive/negative/overall percent agreement for the Leuven versus Myriad HRD status was 95%/86%/91%, respectively. Tumours were HRD+ in 55% and 52%, respectively. In Leuven HRD+ patients, 5 years PFS (5yPFS) was 48.6% versus 20.3% (HR 0.431; 95% confidence intervals (CI) 0.312–0.595) for olaparib versus placebo, respectively (Myriad test 0.409; 95% CI 0.292–0.572). In Leuven HRD+/BRCAwt patients 5yPFS was 41.3% versus 12.6% (HR 0.497; 95% CI 0.316–0.783), and 43.6% versus 13.3% (HR 0.435; 95% CI 0.261–0.727) for the Myriad test. 5yOS was prolonged in the HRD+ subgroup with both tests 67.2% versus 54.4% (HR 0.663; 95% CI 0.442–0.995) for the Leuven test, and 68.0% versus 51.8% (HR 0.596 95% CI 0.393–0.904) for the Myriad test. HRD status was undetermined in 10.7% and 9.4% of the samples, respectively. Conclusions: A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.

Published
2023

15. LOSS OF SKELETAL MUSCLE MASS DURING NEO-ADJUVANT CHEMOTHERAPY AND THE RELATION TO SURVIVAL IN PATIENTS WITH OVARIAN CANCER; A PROSPECTIVE ANALYSIS OF THE OVHIPEC-1 COHORT: EP1009

Author

Ubachs, J, Koole, S, Bruijs, L, Lahaye, M, Fabris, C, van Leeuwen, Schagen J, Schreuder, H, Hermans, R, de Hingh, I, van der Velden, J, Arts, H, Massuger, L, Bastings, J, Kruitwagen, R, Lambrechts, S, Damink, Olde S, Rensen, S, van Gorp, T, Sonke, G, and van Driel, W

Published
2019
Full Text
View/download PDF

18. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Author

Kang, E-Y, Weir, A, Meagher, NS, Farrington, K, Nelson, GS, Ghatage, P, Lee, C-H, Riggan, MJ, Bolithon, A, Popovic, G, Leung, B, Tang, K, Lambie, N, Millstein, J, Alsop, J, Anglesio, MS, Ataseven, B, Barlow, E, Beckmann, MW, Berger, J, Bisinotto, C, Boesmueller, H, Boros, J, Brand, AH, Brooks-Wilson, A, Brucker, SY, Carney, ME, Casablanca, Y, Cazorla-Jimenez, A, Cohen, PA, Conrads, TP, Cook, LS, Coulson, P, Courtney-Brooks, M, Cramer, DW, Crowe, P, Cunningham, JM, Cybulski, C, Darcy, KM, El-Bahrawy, MA, Elishaev, E, Erber, R, Farrell, R, Fereday, S, Fischer, A, Garcia, MJ, Gayther, SA, Gentry-Maharaj, A, Gilks, CB, Grube, M, Harnett, PR, Harrington, SP, Harter, P, Hartmann, A, Hecht, JL, Heikaus, S, Hein, A, Heitz, F, Hendley, J, Hernandez, BY, Hernando Polo, S, Heublein, S, Hirasawa, A, Hogdall, E, Hogdall, CK, Horlings, HM, Huntsman, DG, Huzarski, T, Jewell, A, Jimenez-Linan, M, Jones, ME, Kaufmann, SH, Kennedy, CJ, Khabele, D, Kommoss, FKF, Kruitwagen, RFPM, Lambrechts, D, Le, ND, Lener, M, Lester, J, Leung, Y, Linder, A, Loverix, L, Lubinski, J, Madan, R, Maxwell, GL, Modugno, F, Neuhausen, SL, Olawaiye, A, Olbrecht, S, Orsulic, S, Palacios, J, Pearce, CL, Pike, MC, Quinn, CM, Mohan, GR, Rodriguez-Antona, C, Ruebner, M, Ryan, A, Salfinger, SG, Sasamoto, N, Schildkraut, JM, Schoemaker, MJ, Shah, M, Sharma, R, Shvetsov, YB, Singh, N, Sonke, GS, Steele, L, Stewart, CJR, Sundfeldt, K, Swerdlow, AJ, Talhouk, A, Tan, A, Taylor, SE, Terry, KL, Toloczko, A, Traficante, N, Van de Vijver, KK, van der Aa, MA, Van Gorp, T, Van Nieuwenhuysen, E, Van-Wagensveld, L, Vergote, I, Vierkant, RA, Wang, C, Wilkens, LR, Winham, SJ, Wu, AH, Benitez, J, Berchuck, A, Candido Dos Reis, FJ, DeFazio, A, Fasching, PA, Goode, EL, Goodman, MT, Gronwald, J, Karlan, BY, Kommoss, S, Menon, U, Sinn, H-P, Staebler, A, Brenton, JD, Bowtell, DD, Pharoah, PDP, Ramus, SJ, Kobel, M, Kang, E-Y, Weir, A, Meagher, NS, Farrington, K, Nelson, GS, Ghatage, P, Lee, C-H, Riggan, MJ, Bolithon, A, Popovic, G, Leung, B, Tang, K, Lambie, N, Millstein, J, Alsop, J, Anglesio, MS, Ataseven, B, Barlow, E, Beckmann, MW, Berger, J, Bisinotto, C, Boesmueller, H, Boros, J, Brand, AH, Brooks-Wilson, A, Brucker, SY, Carney, ME, Casablanca, Y, Cazorla-Jimenez, A, Cohen, PA, Conrads, TP, Cook, LS, Coulson, P, Courtney-Brooks, M, Cramer, DW, Crowe, P, Cunningham, JM, Cybulski, C, Darcy, KM, El-Bahrawy, MA, Elishaev, E, Erber, R, Farrell, R, Fereday, S, Fischer, A, Garcia, MJ, Gayther, SA, Gentry-Maharaj, A, Gilks, CB, Grube, M, Harnett, PR, Harrington, SP, Harter, P, Hartmann, A, Hecht, JL, Heikaus, S, Hein, A, Heitz, F, Hendley, J, Hernandez, BY, Hernando Polo, S, Heublein, S, Hirasawa, A, Hogdall, E, Hogdall, CK, Horlings, HM, Huntsman, DG, Huzarski, T, Jewell, A, Jimenez-Linan, M, Jones, ME, Kaufmann, SH, Kennedy, CJ, Khabele, D, Kommoss, FKF, Kruitwagen, RFPM, Lambrechts, D, Le, ND, Lener, M, Lester, J, Leung, Y, Linder, A, Loverix, L, Lubinski, J, Madan, R, Maxwell, GL, Modugno, F, Neuhausen, SL, Olawaiye, A, Olbrecht, S, Orsulic, S, Palacios, J, Pearce, CL, Pike, MC, Quinn, CM, Mohan, GR, Rodriguez-Antona, C, Ruebner, M, Ryan, A, Salfinger, SG, Sasamoto, N, Schildkraut, JM, Schoemaker, MJ, Shah, M, Sharma, R, Shvetsov, YB, Singh, N, Sonke, GS, Steele, L, Stewart, CJR, Sundfeldt, K, Swerdlow, AJ, Talhouk, A, Tan, A, Taylor, SE, Terry, KL, Toloczko, A, Traficante, N, Van de Vijver, KK, van der Aa, MA, Van Gorp, T, Van Nieuwenhuysen, E, Van-Wagensveld, L, Vergote, I, Vierkant, RA, Wang, C, Wilkens, LR, Winham, SJ, Wu, AH, Benitez, J, Berchuck, A, Candido Dos Reis, FJ, DeFazio, A, Fasching, PA, Goode, EL, Goodman, MT, Gronwald, J, Karlan, BY, Kommoss, S, Menon, U, Sinn, H-P, Staebler, A, Brenton, JD, Bowtell, DD, Pharoah, PDP, Ramus, SJ, and Kobel, M

Abstract

BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high-level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08-1.47, p = .034, and HR, 1.18; 95% CI, 1.05-1.32, p = .015, respectively). This was also true for cases with combined high-level amplification/overexpression (HR, 1.26; 95% CI, 1.09-1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1-SD increase; 95% CI, 0.94-1.06; p = .58). CCNE1 high-level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large-scale validation that CCNE1 high-level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.

Published
2023

19. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery

Author

Phung, MT, Webb, PM, DeFazio, A, Fereday, S, Lee, AW, Bowtell, DDL, Fasching, PA, Goode, EL, Goodman, MT, Karlan, BY, Lester, J, Matsuo, K, Modugno, F, Brenton, JD, Van Gorp, T, Pharoah, PDP, Schildkraut, JM, McLean, K, Meza, R, Mukherjee, B, Richardson, J, Grout, B, Chase, A, Deurloo, CM, Terry, KL, Hanley, GE, Pike, MC, Berchuck, A, Ramus, SJ, Pearce, CL, Phung, MT, Webb, PM, DeFazio, A, Fereday, S, Lee, AW, Bowtell, DDL, Fasching, PA, Goode, EL, Goodman, MT, Karlan, BY, Lester, J, Matsuo, K, Modugno, F, Brenton, JD, Van Gorp, T, Pharoah, PDP, Schildkraut, JM, McLean, K, Meza, R, Mukherjee, B, Richardson, J, Grout, B, Chase, A, Deurloo, CM, Terry, KL, Hanley, GE, Pike, MC, Berchuck, A, Ramus, SJ, and Pearce, CL

Abstract

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify factors associated with having macroscopic residual disease. We analyzed 12 lifestyle and personal exposures known to be related to ovarian cancer risk or inflammation to identify those associated with having residual disease after surgery. METHODS: This analysis used data on 2054 patients with advanced stage HGSC from the Ovarian Cancer Association Consortium. The exposures were body mass index, breastfeeding, oral contraceptive use, depot-medroxyprogesterone acetate use, endometriosis, first-degree family history of ovarian cancer, incomplete pregnancy, menopausal hormone therapy use, menopausal status, parity, smoking, and tubal ligation. Logistic regression models were fit to assess the association between these exposures and having residual disease following PCS. RESULTS: Menopausal estrogen-only therapy (ET) use was associated with 33% lower odds of having macroscopic residual disease compared to never use (OR = 0.67, 95%CI 0.46-0.97, p = 0.033). Compared to nulliparous women, parous women who did not breastfeed had 36% lower odds of having residual disease (OR = 0.64, 95%CI 0.43-0.94, p = 0.022), while there was no association among parous women who breastfed (OR = 0.90, 95%CI 0.65-1.25, p = 0.53). CONCLUSIONS: The association between ET and having no macroscopic residual disease is plausible given a strong underlying biologic hypothesis between this exposure and diagnosis with HGSC. If this or the parity finding is replicated, these factors could be included in risk stratification models to determine whether HGSC patients should receive PCS or neoadjuvant chemotherapy.

Published
2023

20. Reply to Z.R. McCaw et al

Author

Matulonis, U, Lorusso, D, Oaknin, A, Pignata, S, Dean, A, Denys, H, Colombo, N, Van Gorp, T, Konner, J, Marin, M, Harter, P, Murphy, C, Wang, J, Noble, E, Esteves, B, Method, M, Coleman, R, Matulonis, Ursula A, Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G, Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L, Matulonis, U, Lorusso, D, Oaknin, A, Pignata, S, Dean, A, Denys, H, Colombo, N, Van Gorp, T, Konner, J, Marin, M, Harter, P, Murphy, C, Wang, J, Noble, E, Esteves, B, Method, M, Coleman, R, Matulonis, Ursula A, Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G, Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, and Coleman, Robert L

Published
2023

21. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Author

Colombo, N, Van Gorp, T, Matulonis, U, Oaknin, A, Grisham, R, Fleming, G, Olawaiye, A, Nguyen, D, Greenstein, A, Custodio, J, Pashova, H, Tudor, I, Lorusso, D, Colombo, Nicoletta, Van Gorp, Toon, Matulonis, Ursula A, Oaknin, Ana, Grisham, Rachel N, Fleming, Gini F, Olawaiye, Alexander B, Nguyen, Dorothy D, Greenstein, Andrew E, Custodio, Joseph M, Pashova, Hristina I, Tudor, Iulia C, Lorusso, Domenica, Colombo, N, Van Gorp, T, Matulonis, U, Oaknin, A, Grisham, R, Fleming, G, Olawaiye, A, Nguyen, D, Greenstein, A, Custodio, J, Pashova, H, Tudor, I, Lorusso, D, Colombo, Nicoletta, Van Gorp, Toon, Matulonis, Ursula A, Oaknin, Ana, Grisham, Rachel N, Fleming, Gini F, Olawaiye, Alexander B, Nguyen, Dorothy D, Greenstein, Andrew E, Custodio, Joseph M, Pashova, Hristina I, Tudor, Iulia C, and Lorusso, Domenica

Abstract

PURPOSE: Despite therapeutic advances, outcomes for patients with platinum-resistant/refractory ovarian cancer remain poor. Selective glucocorticoid receptor modulation with relacorilant may restore chemosensitivity and enhance chemotherapy efficacy. METHODS: This three-arm, randomized, controlled, open-label phase II study (ClinicalTrials.gov identifier: NCT03776812) enrolled women with recurrent, platinum-resistant/refractory, high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer, or ovarian carcinosarcoma treated with ≤4 prior chemotherapeutic regimens. Patients were randomly assigned 1:1:1 to (1) nab-paclitaxel (80 mg/m2) + intermittent relacorilant (150 mg the day before, of, and after nab-paclitaxel); (2) nab-paclitaxel (80 mg/m2) + continuous relacorilant (100 mg once daily); or (3) nab-paclitaxel monotherapy (100 mg/m2). Nab-paclitaxel was administered on days 1, 8, and 15 of each 28-day cycle. The primary end point was progression-free survival (PFS) by investigator assessment; objective response rate (ORR), duration of response (DOR), overall survival (OS), and safety were secondary end points. RESULTS: A total of 178 women were randomly assigned. Intermittent relacorilant + nab-paclitaxel improved PFS (hazard ratio [HR], 0.66; log-rank test P = .038; median follow-up, 11.1 months) and DOR (HR, 0.36; P = .006) versus nab-paclitaxel monotherapy, while ORR was similar across arms. At the preplanned OS analysis (median follow-up, 22.5 months), the OS HR was 0.67 (P = .066) for the intermittent arm versus nab-paclitaxel monotherapy. Continuous relacorilant + nab-paclitaxel showed numerically improved median PFS but did not result in significant improvement over nab-paclitaxel monotherapy. Adverse events were comparable across study arms, with neutropenia, anemia, peripheral neuropathy, and fatigue/asthenia being the most common grade ≥3 adverse events. CONCLUSION: Intermittent relacorilant + nab-paclitaxel improved

Published
2023

25. 592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

Author

Matulonis, U.A., primary, Moore, K.N., additional, Lorusso, D., additional, Oaknin, A., additional, Pignata, S., additional, Denys, H., additional, Colombo, N., additional, Van Gorp, T., additional, Konner, J., additional, Romeo Marin, M., additional, Harter, P., additional, Murphy, C., additional, Tu, Y., additional, Zhu, F., additional, Esteves, B., additional, Method, M., additional, Birrer, M.J., additional, Coleman, R.L., additional, and O'Malley, D., additional

Published
2022
Full Text
View/download PDF

26. 526MO Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)

Author

Cibula, D., primary, Köhler, C., additional, Bajsová, S., additional, Sebestova, S., additional, Zapardiel, I., additional, Di Martino, G., additional, van Lonkhuijzen, L.R., additional, Sehnal, B., additional, Arencibia Sánchez, O., additional, Gil Ibañez, B., additional, Martinelli, F., additional, Presl, J., additional, Minář, L., additional, Marek, R., additional, Kascak, P., additional, Havelka, P., additional, Michal, M., additional, Van Gorp, T., additional, Nemejcova, K., additional, and Kocian, R., additional

Published
2022
Full Text
View/download PDF

27. 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer

Author

Moore, K.N., primary, Lorusso, D., additional, Oaknin, A., additional, Pignata, S., additional, Denys, H., additional, Colombo, N., additional, Van Gorp, T., additional, Konner, J., additional, Romeo Marin, M., additional, Harter, P., additional, Murphy, C., additional, Tu, Y., additional, Zhu, F., additional, Esteves, B., additional, Method, M., additional, Birrer, M.J., additional, Coleman, R.L., additional, Matulonis, U.A., additional, and O'Malley, D., additional

Published
2022
Full Text
View/download PDF

28. 536P Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study

Author

Colombo, N., primary, Van Gorp, T., additional, Matulonis, U.A., additional, Oaknin, A., additional, Grisham, R.N., additional, Fleming, G., additional, Olawaiye, A., additional, Tudor, I.C., additional, Pashova, H.I., additional, and Lorusso, D., additional

Published
2022
Full Text
View/download PDF

32. LBA28 ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

Author

Van Gorp, T., Rob, L., Lu, W., Backes, F., Ortaç, F., Hasegawa, K., Hietanen, S.H., Savarese, A., Laenen, A., Kim, Y.M., Bodnar, L., Barretina Ginesta, M.P., Gilbert, L., Pothuri, B., Chen, X., Lichfield, J., Wang, W., Orlowski, R.J., Lortholary, A., and Slomovitz, B.M.

Published
2024
Full Text
View/download PDF

33. 746P Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression

Author

Coffman, L. Gardner, You, B., Hamilton, E.P., Garcia, Y. Garcia, Moore, K.N., Sonnenburg, D., Scambia, G., Derio, S., Pepin, J. Thomes, Klasa-Mazurkiewicz, D., Tromp, J., Breuer, S., Weroha, S., Sukhina, O., Wang, Y., Stec, J.J., and Van Gorp, T.

Published
2024
Full Text
View/download PDF

34. 731P Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy

Author

Mirza, M.R., Mathews, C., Gilbert, L., Bjorge, L., Ring, K., Pishchyk, M.M., Pennington, K., Segev, Y., Powell, M.A., Van Gorp, T., Bender, D., Schneider, K., Miller, R., Armstrong, A., Canturia, G., Gogoi, R., Antony, G., Stevens, S., Valabrega, G., and Landrum, L.M.

Published
2024
Full Text
View/download PDF

36. VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Author

Vergote, I.B., Fidalgo, A. Pérez, Hamilton, E., Valabrega, G., Van Gorp, T., Sehouli, J., Cibula, D., Levy, T., Welch, S., Richardson, D.L., Alía, E.M. Guerra, Scambia, G., Henry, S., Wimberger, P., Miller, D., Martínez, J., Monk, B.J., Shacham, S., Mirza, M.R., and Makker, V.

Published
2022
Full Text
View/download PDF

39. EPV107/#258 ENGOT-EN11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer

Author

Van Gorp, T, primary, Mirza, M, additional, Lortholary, A, additional, Vergote, I, additional, Cibula, D, additional, Walther, A, additional, Savarese, A, additional, Barretina-Ginesta, M-P, additional, Ortaç, F, additional, Papadimitriou, C, additional, Bodnar, L, additional, Lai, C-H, additional, Hasegawa, K, additional, Xie, X, additional, Barber, EL, additional, Coleman, RL, additional, Keefe, S, additional, Orlowski, R, additional, and Slomovitz, B, additional

Published
2021
Full Text
View/download PDF

40. O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results

Author

Monk, B, primary, Van Gorp, T, additional, Lorusso, D, additional, Eilish O’Cearbhaill, R, additional, Westermann, A, additional, Banerjee, S, additional, Collins, D, additional, Klat, J, additional, Madsen, K, additional, Baurain, J-F, additional, Jackson, A, additional, Boere, I, additional, Pignata, S, additional, Gort, E, additional, Moroney, J, additional, Soumaoro, I, additional, Andreassen, CM, additional, Nicacio, L, additional, Gennigens, C, additional, and Vergote, I, additional

Published
2021
Full Text
View/download PDF

42. 185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer

Author

Van Gorp, T, primary, Mirza, MR, additional, Lortholary, A, additional, Vergote, IB, additional, Cibula, D, additional, Walther, A, additional, Savarese, A, additional, Barretina-Ginesta, MP, additional, Ortac, FU, additional, Papadimitriou, C, additional, Bodnar, L, additional, Lai, CH, additional, Hasegawa, K, additional, Xie, X, additional, Barber, EL, additional, Coleman, R, additional, Lichfield, J, additional, Grandhi, A, additional, and Slomovitz, B, additional

Published
2021
Full Text
View/download PDF

44. 201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative

Author

Pujade-Lauraine, E, primary, Christinat, Y, additional, D’incalci, M, additional, Schouten, P, additional, Buisson, A, additional, Heukamp, LC, additional, Van Gorp, T, additional, Kramer, C, additional, Mckee, T, additional, Marchini, S, additional, Hahnen, E, additional, Saintigny, P, additional, Ioana Braicu, E, additional, Vergote, IB, additional, Yaniz-Galende, E, additional, and Ray-Coquard, I, additional

Published
2021
Full Text
View/download PDF

45. 415 Single-cell map of the dynamic changes underlying platinum-based chemotherapy with or without bevacizumab in high-grade serous tubo-ovarian carcinoma

Author

Olbrecht, S, primary, Busschaert, P, additional, Loverix, L, additional, Vandestichele, A, additional, Laga, T, additional, Van Gorp, T, additional, Van Nieuwenhuysen, E, additional, Han, S, additional, Baert, T, additional, Van Rompuy, AS, additional, Lambrechts, D, additional, and Vergote, I, additional

Published
2021
Full Text
View/download PDF

46. 199 Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

Author

Vergote, IB, primary, Van Nieuwenhuysen, E, additional, Casado, A, additional, Laenen, A, additional, Lorusso, D, additional, Braicu, I, additional, Guerra-Alia, E, additional, Zola, P, additional, Wimberger, P, additional, Debruyne, P, additional, Falcó, E, additional, Ferrero, A, additional, Muallem, MZ, additional, Kerger, J, additional, Garcia Martinez, E, additional, Pignata, S, additional, Sehouli, J, additional, Van Gorp, T, additional, Gennigens, C, additional, and Rubio Pérez, MJ, additional

Published
2021
Full Text
View/download PDF

47. 950 Sensitivity and false negativity of SLN frozen sectionhistological evaluation in the sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

Author

Kocian, R, primary, Kohler, C, additional, Bajsová, S, additional, Sebestova, S, additional, Zapardiel, I, additional, Martino, GDI, additional, Van Lonkhuijzen, L, additional, Sehnal, B, additional, Arencibia Sanchez, O, additional, Gil-Ibanez, B, additional, Martinelli, F, additional, Presl, J, additional, Minar, L, additional, Marek, R, additional, Kascak, P, additional, Havelka, P, additional, Michal, M, additional, Van Gorp, T, additional, Nemejcova, K, additional, and Cibula, D, additional

Published
2021
Full Text
View/download PDF

48. 184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer

Author

Concin, N, primary, Hamilton, E, additional, Randall, LM, additional, Banerjee, S, additional, Mileshkin, L, additional, Coleman, RL, additional, Monk, B, additional, Mirza, MR, additional, Savarese, A, additional, Ray-Coquard, I, additional, Perez Fidalgo, JA, additional, Bernardo, P, additional, Putiri, E, additional, Burger, R, additional, Mosher, R, additional, Richardson, D, additional, Cibula, D, additional, Madry, R, additional, Chekerov, R, additional, and Van Gorp, T, additional

Published
2021
Full Text
View/download PDF

49. 721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study

Author

Colombo, N., primary, Nguyen, D.D., additional, Fleming, G.F., additional, Grisham, R.N., additional, Lorusso, D., additional, Van Gorp, T., additional, Oaknin, A., additional, Pashova, H.I., additional, and Grauer, A., additional

Published
2021
Full Text
View/download PDF

50. SENSITIVITY AND FALSE NEGATIVITY OF SLN FROZEN SECTIONHISTOLOGICAL EVALUATION IN THE SENTIX TRIAL (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

Author

Kocian, R., Kohler, C., Bajsova, S., Sebestova, S., Zapardiel, I., Martino, G. D. I., Van Lonkhuijzen, L., Sehnal, B., Arencibia Sanchez, O., Gil-Ibanez, B., Martinelli, F., Presl, J., Minar, L., Marek, R., Kascak, P., Havelka, P., Michal, M., Van Gorp, T., Nemejcova, K., Cibula, D., Obstetrics and Gynaecology, and CCA - Cancer Treatment and Quality of Life

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results